VCRE (Vicore Pharma Holding AB) Cyclically Adjusted PB Ratio: (As of Jul. 07, 2026)


VCRE Vicore Pharma Holding AB VCRE
13 GF Score
Price $15.60
! 5 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Vicore Pharma Holding AB  (NAS:VCRE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Vicore Pharma Holding AB Cyclically Adjusted PB Ratio Related Terms


Vicore Pharma Holding AB Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicore Pharma Holding AB Cyclically Adjusted PB Ratio Chart

Vicore Pharma Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 1.36 1.89

Vicore Pharma Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.14 1.24 2.20 1.89 1.70

VCRE vs : Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicore Pharma Holding AB Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Cyclically Adjusted PB Ratio falls into.


VCRE
13GF Score
Vicore Pharma Holding AB VCRE
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Vicore Pharma Holding AB's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Vicore Pharma Holding AB's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.378/133.5600*133.5600
=0.378

Current CPI (Mar. 2026) = 133.5600.

Vicore Pharma Holding AB Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.657 101.019 0.869
201609 0.627 101.138 0.828
201612 0.237 102.022 0.310
201703 0.616 102.022 0.806
201706 0.752 102.752 0.977
201709 0.804 103.279 1.040
201712 0.369 103.793 0.475
201803 0.766 103.962 0.984
201806 0.749 104.875 0.954
201809 0.559 105.679 0.706
201812 0.933 105.912 1.177
201903 0.691 105.886 0.872
201906 0.619 106.742 0.775
201909 0.547 107.214 0.681
201912 0.661 107.766 0.819
202003 0.581 106.563 0.728
202006 0.565 107.498 0.702
202009 0.749 107.635 0.929
202012 0.683 108.296 0.842
202103 0.999 108.360 1.231
202106 0.903 108.928 1.107
202109 0.726 110.338 0.879
202112 0.572 112.486 0.679
202203 0.413 114.825 0.480
202206 0.308 118.384 0.347
202209 0.199 122.296 0.217
202212 0.331 126.365 0.350
202303 0.255 127.042 0.268
202306 0.300 129.407 0.310
202309 0.445 130.224 0.456
202312 0.387 131.912 0.392
202403 0.409 132.205 0.413
202406 0.361 132.716 0.363
202409 0.322 132.304 0.325
202412 0.438 132.987 0.440
202503 0.429 132.825 0.431
202506 0.405 133.699 0.405
202509 0.363 133.480 0.363
202512 0.419 133.390 0.420
202603 0.378 133.560 0.378

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Vicore Pharma Holding AB Business Description

Comparable Companies
Other Exchanges VICO:Sweden6Y4:Germany
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
13GF Score

Get the complete analysis for VCRE

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.60
Price